Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial
Vical Incorporated announced today that the last patient completed their final assessment during the one year follow-up period in the multinational Phase 3 registration trial of ASP0113 in hematopoietic cell transplant recipients. The trial completed enrollment in September 2016 with a total of 515 subjects.
from Biotech News
0 Comments